Effect of Different Doses of Tomato Lycopene on Blood Pressure in Pre-hypertensive Otherwise Healthy Subjects

NCT ID: NCT00637858

Last Updated: 2013-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effect of different doses of tomato extract (contain Lyc-o-Mato 6% Oleoresin which Contain: 5, 15 mg lycopene , in addition to Beta-carotene (0.15%), phytoene, and phytofluene (1%); and vitamin E (2%), phospholipids (15%), and phytosterols (0.6%) suspended in tomato oleoresin oil) compared with synthetic lycopene on blood pressure and plasma lycopene levels in never treated pre-hypertensive otherwise healthy subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).

2

Lyc-o-Mato 5mg

Group Type ACTIVE_COMPARATOR

Lyc-O-Mato 5mg

Intervention Type DIETARY_SUPPLEMENT

Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

3

Lyc-o-Mato 15mg

Group Type ACTIVE_COMPARATOR

Lyc-O-Mato 15mg

Intervention Type DIETARY_SUPPLEMENT

Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

4

Lyc-o-Mato 30mg

Group Type ACTIVE_COMPARATOR

Lyc-O-Mato 30mg

Intervention Type DIETARY_SUPPLEMENT

Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

5

Lycopene capsules (non Lyc-o-mato) 15 mg

Group Type ACTIVE_COMPARATOR

Lycopene capsules (non Lyc-o-mato) 15 mg

Intervention Type DIETARY_SUPPLEMENT

Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lyc-O-Mato 5mg

Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

Intervention Type DIETARY_SUPPLEMENT

Lyc-O-Mato 15mg

Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

Intervention Type DIETARY_SUPPLEMENT

Lyc-O-Mato 30mg

Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

Intervention Type DIETARY_SUPPLEMENT

Lycopene capsules (non Lyc-o-mato) 15 mg

Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 35-60,
* No antihypertensive treatment in the past or present,
* 135\< SBP\< 145 or 85\<DBP\<95,
* Informed consent signed,

Exclusion Criteria

* Unwilling to participate in the study,
* Treated essential,
* secondary or complicated hypertension,
* SBP lower than 135 or higher than 145 mmHg,
* DBP lower than 85 or higher than 95 mmHg,
* Use of other medications (statins, NSAI ect..),
* Known allergy to tomato, carotenoids, or vitamin E,
* Diabetes Mellitus,
* Obesity BMI\>32,
* Significant dyslipidemia,
* Patients with ischemic pain, S/P MI, PTCA or CABG, LVH or CHF,
* Smoker,
* Valvular heart disease,
* PVD,
* Cerebrovascular disease, s/p CVA, TIA,
* Any kind of kidney disease (creatinine\>1.6),
* Chronic liver disease(elevated AST and ALT at least by 2 times of the normal range),
* Alcohol abuse,
* History of GI disease or surgery,
* History of malignancy in the past 5 years,
* History of autoimmune disease,
* Participation in other researches protocol
Minimum Eligible Age

35 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

LycoRed Ltd.

INDUSTRY

Sponsor Role collaborator

The S. Daniel Abraham International Center for Health and Nutrition

OTHER

Sponsor Role collaborator

Soroka University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ester Paran, Professor

Role: PRINCIPAL_INVESTIGATOR

Hypertension clinic of the Soroka University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hypertension Unit

Beersheba, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

References

Explore related publications, articles, or registry entries linked to this study.

Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study. Am Heart J. 2006 Jan;151(1):100. doi: 10.1016/j.ahj.2005.05.008.

Reference Type BACKGROUND
PMID: 16368299 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SOR459407CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lycopene In Preventing of Prostate Cancer
NCT00006078 COMPLETED PHASE1
Vitamin A Value of Spirulina Carotenoids in Humans
NCT00680277 COMPLETED PHASE1/PHASE2